Lexaria Bioscience Corp (NASDAQ: LEXX)’s stock price has soared by 25.61 in relation to previous closing price of 2.46. Nevertheless, the company has seen a gain of 37.95% in its stock price over the last five trading days. Newsfile Corp reported 2024-03-21 that Kelowna, British Columbia–(Newsfile Corp. – March 21, 2024) – Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings.
Is It Worth Investing in Lexaria Bioscience Corp (NASDAQ: LEXX) Right Now?
LEXX has 36-month beta value of 1.01. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LEXX is 11.22M, and currently, short sellers hold a 3.88% ratio of that float. The average trading volume of LEXX on May 01, 2024 was 489.78K shares.
LEXX’s Market Performance
LEXX stock saw a decrease of 37.95% in the past week, with a monthly decline of -9.65% and a quarterly a decrease of 108.78%. The volatility ratio for the week is 12.10%, and the volatility levels for the last 30 days are 11.55% for Lexaria Bioscience Corp (LEXX). The simple moving average for the past 20 days is 21.50% for LEXX’s stock, with a 80.68% simple moving average for the past 200 days.
LEXX Trading at -1.02% from the 50-Day Moving Average
After a stumble in the market that brought LEXX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.89% of loss for the given period.
Volatility was left at 11.55%, however, over the last 30 days, the volatility rate increased by 12.10%, as shares sank -10.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.39% upper at present.
During the last 5 trading sessions, LEXX rose by +37.95%, which changed the moving average for the period of 200-days by +273.32% in comparison to the 20-day moving average, which settled at $2.52. In addition, Lexaria Bioscience Corp saw 147.20% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for LEXX
Current profitability levels for the company are sitting at:
- -21.39 for the present operating margin
- 0.91 for the gross margin
The net margin for Lexaria Bioscience Corp stands at -22.06. The total capital return value is set at -1.69. Equity return is now at value -101.53, with -95.89 for asset returns.
Based on Lexaria Bioscience Corp (LEXX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -37.59.
Currently, EBITDA for the company is -6.17 million with net debt to EBITDA at 0.32. When we switch over and look at the enterprise to sales, we see a ratio of 132.05. The receivables turnover for the company is 0.52for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 66.29.
Conclusion
To put it simply, Lexaria Bioscience Corp (LEXX) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
